At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,092 enrolled
Drug / intervention
QVM149 150/50/160 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
In Brief
A Phase 3 clinical trial evaluating QVM149 150/50/160, QVM149 150/50/80, and 3 other interventions for Asthma. Completed, enrolled 3,092 participants across 403 sites in 41 countries.
Detailed Summary
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionJun 2019
TodayJul 2026
First PostedOct 8, 2015
Enrollment StartDec 8, 2015
Primary CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.7 years ago
Interventions
QVM149 150/50/160drug
QVM149 150/50/80drug
QMF149 150/320drug
QMF149 150/160drug
salmeterol/fluticasonedrug